Sector News

Lilly hands its oncology baton to R&D executive Anne White

September 3, 2018
Life sciences

With oncology head Sue Mahony retiring today, Eli Lilly has her replacement ready to step in.

The company has promoted Anne White, currently VP of portfolio management for Lilly’s Chorus and next gen R&D units, to take on the role of SVP and president of Lilly Oncology, a unit Lilly says will be key to its growth future. She’ll step in as of this Saturday, reporting directly to Lilly CEO David Ricks.

White will have big shoes to fill, as Mahony—who said in May that she’d depart—saw the company through some key changes in her 18 years with the drugmaker. She spearheaded the launch of Verzenio, Lilly’s answer to Pfizer breast cancer blockbuster Ibrance, last year, and she managed the integration of Lilly’s 2008 ImClone acquisition as well.

White, though, brings more than 25 years of biopharma experience of her own to the table. Before landing in her current position, she held various jobs both inside and outside of Lilly, including COO of oncology. Plus, White’s R&D background will likely come in handy as Lilly looks to advance a number of oncology pipeline candidates, including next-gen immuno-oncology therapies.

“Her experience leading significant change transformation within the company will be incredibly valuable as we look toward the future,” Ricks said in a statement, adding that she brings “a wealth of … expertise and leadership to our executive team.”

White will draw on that experience to keep the Verzenio launch rolling and pump up other recent launches, too. Lilly is counting on drugs Cyramza and Lartruvo, in addition to the breast-cancer fighter, to help it meet 2018 sales forecasts of $23 billion to $23.5 billion.

Meanwhile, it’s been a big week for commercial appointments around the industry. Earlier in the week, Gilead poached Laura Hamill from Amgen to take its top commercial post, while Bristol-Myers Squibb promoted Christopher Boerner to commercial head to replace Murdo Gordon, who left for Amgen.

By Carly Helfand

Source: Fierce Pharma

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend